Rep. Avery Bourne

Filed: 3/13/2017

 

 


 

 


 
10000HB2534ham001LRB100 08419 RLC 23080 a

1
AMENDMENT TO HOUSE BILL 2534

2    AMENDMENT NO. ______. Amend House Bill 2534 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Illinois Controlled Substances Act is
5amended by changing Sections 204, 206, 208, 401, and 402 as
6follows:
 
7    (720 ILCS 570/204)  (from Ch. 56 1/2, par. 1204)
8    Sec. 204. (a) The controlled substances listed in this
9Section are included in Schedule I.
10    (b) Unless specifically excepted or unless listed in
11another schedule, any of the following opiates, including their
12isomers, esters, ethers, salts, and salts of isomers, esters,
13and ethers, whenever the existence of such isomers, esters,
14ethers and salts is possible within the specific chemical
15designation:
16        (1) Acetylmethadol;

 

 

10000HB2534ham001- 2 -LRB100 08419 RLC 23080 a

1        (1.1) Acetyl-alpha-methylfentanyl
2    (N-[1-(1-methyl-2-phenethyl)-
3    4-piperidinyl]-N-phenylacetamide);
4        (2) Allylprodine;
5        (3) Alphacetylmethadol, except
6    levo-alphacetylmethadol (also known as levo-alpha-
7    acetylmethadol, levomethadyl acetate, or LAAM);
8        (4) Alphameprodine;
9        (5) Alphamethadol;
10        (6) Alpha-methylfentanyl
11    (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
12    propionanilide;  1-(1-methyl-2-phenylethyl)-4-(N-
13    propanilido) piperidine;
14        (6.1) Alpha-methylthiofentanyl
15    (N-[1-methyl-2-(2-thienyl)ethyl-
16    4-piperidinyl]-N-phenylpropanamide);
17        (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
18        (7.1) PEPAP
19    (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
20        (8) Benzethidine;
21        (9) Betacetylmethadol;
22        (9.1) Beta-hydroxyfentanyl
23    (N-[1-(2-hydroxy-2-phenethyl)-
24    4-piperidinyl]-N-phenylpropanamide);
25        (10) Betameprodine;
26        (11) Betamethadol;

 

 

10000HB2534ham001- 3 -LRB100 08419 RLC 23080 a

1        (12) Betaprodine;
2        (13) Clonitazene;
3        (14) Dextromoramide;
4        (15) Diampromide;
5        (16) Diethylthiambutene;
6        (17) Difenoxin;
7        (18) Dimenoxadol;
8        (19) Dimepheptanol;
9        (20) Dimethylthiambutene;
10        (21) Dioxaphetylbutyrate;
11        (22) Dipipanone;
12        (23) Ethylmethylthiambutene;
13        (24) Etonitazene;
14        (25) Etoxeridine;
15        (26) Furethidine;
16        (27) Hydroxpethidine;
17        (28) Ketobemidone;
18        (29) Levomoramide;
19        (30) Levophenacylmorphan;
20        (31) 3-Methylfentanyl
21    (N-[3-methyl-1-(2-phenylethyl)-
22    4-piperidyl]-N-phenylpropanamide);
23        (31.1) 3-Methylthiofentanyl
24    (N-[(3-methyl-1-(2-thienyl)ethyl-
25    4-piperidinyl]-N-phenylpropanamide);
26        (32) Morpheridine;

 

 

10000HB2534ham001- 4 -LRB100 08419 RLC 23080 a

1        (33) Noracymethadol;
2        (34) Norlevorphanol;
3        (35) Normethadone;
4        (36) Norpipanone;
5        (36.1) Para-fluorofentanyl
6    (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
7    4-piperidinyl]propanamide);
8        (37) Phenadoxone;
9        (38) Phenampromide;
10        (39) Phenomorphan;
11        (40) Phenoperidine;
12        (41) Piritramide;
13        (42) Proheptazine;
14        (43) Properidine;
15        (44) Propiram;
16        (45) Racemoramide;
17        (45.1) Thiofentanyl
18    (N-phenyl-N-[1-(2-thienyl)ethyl-
19    4-piperidinyl]-propanamide);
20        (46) Tilidine;
21        (47) Trimeperidine;
22        (48) Beta-hydroxy-3-methylfentanyl (other name:
23    N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
24    N-phenylpropanamide); .
25        (49) Furanyl fentanyl (FU-F);
26        (50) Butyryl fentanyl;

 

 

10000HB2534ham001- 5 -LRB100 08419 RLC 23080 a

1        (51) Valeryl fentanyl;
2        (52) Acetyl fentanyl;
3        (53) Beta-hydroxy-thiofentanyl;
4        (54) 3,4-dichloro-N-[2-
5    (dimethylamino)cyclohexyl]-N-
6    methylbenzamide (U-47700); 
7        (55) 4-chloro-N-[1-[2-
8    (4-nitrophenyl)ethyl]-2-piperidinylidene]-
9    benzenesulfonamide (W-18); 
10        (56) 4-chloro-N-[1-(2-phenylethyl)
11    -2-piperidinylidene]-benzenesulfonamide (W-15); 
12        (57) acrylfentanyl (acryloylfentanyl). 
13    (c) Unless specifically excepted or unless listed in
14another schedule, any of the following opium derivatives, its
15salts, isomers and salts of isomers, whenever the existence of
16such salts, isomers and salts of isomers is possible within the
17specific chemical designation:
18        (1) Acetorphine;
19        (2) Acetyldihydrocodeine;
20        (3) Benzylmorphine;
21        (4) Codeine methylbromide;
22        (5) Codeine-N-Oxide;
23        (6) Cyprenorphine;
24        (7) Desomorphine;
25        (8) Diacetyldihydromorphine (Dihydroheroin);
26        (9) Dihydromorphine;

 

 

10000HB2534ham001- 6 -LRB100 08419 RLC 23080 a

1        (10) Drotebanol;
2        (11) Etorphine (except hydrochloride salt);
3        (12) Heroin;
4        (13) Hydromorphinol;
5        (14) Methyldesorphine;
6        (15) Methyldihydromorphine;
7        (16) Morphine methylbromide;
8        (17) Morphine methylsulfonate;
9        (18) Morphine-N-Oxide;
10        (19) Myrophine;
11        (20) Nicocodeine;
12        (21) Nicomorphine;
13        (22) Normorphine;
14        (23) Pholcodine;
15        (24) Thebacon.
16    (d) Unless specifically excepted or unless listed in
17another schedule, any material, compound, mixture, or
18preparation which contains any quantity of the following
19hallucinogenic substances, or which contains any of its salts,
20isomers and salts of isomers, whenever the existence of such
21salts, isomers, and salts of isomers is possible within the
22specific chemical designation (for the purposes of this
23paragraph only, the term "isomer" includes the optical,
24position and geometric isomers):
25        (1) 3,4-methylenedioxyamphetamine
26    (alpha-methyl,3,4-methylenedioxyphenethylamine,

 

 

10000HB2534ham001- 7 -LRB100 08419 RLC 23080 a

1    methylenedioxyamphetamine, MDA);
2        (1.1) Alpha-ethyltryptamine
3    (some trade or other names: etryptamine;
4    MONASE; alpha-ethyl-1H-indole-3-ethanamine;
5    3-(2-aminobutyl)indole; a-ET; and AET);
6        (2) 3,4-methylenedioxymethamphetamine (MDMA);
7        (2.1) 3,4-methylenedioxy-N-ethylamphetamine
8    (also known as: N-ethyl-alpha-methyl-
9    3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
10    and MDEA);
11        (2.2) N-Benzylpiperazine (BZP);
12        (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
13        (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
14        (4) 3,4,5-trimethoxyamphetamine (TMA);
15        (5) (Blank);
16        (6) Diethyltryptamine (DET);
17        (7) Dimethyltryptamine (DMT);
18        (7.1) 5-Methoxy-diallyltryptamine;
19        (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
20        (9) Ibogaine  (some trade and other names:
21    7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
22    6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
23    indole; Tabernanthe iboga);
24        (10) Lysergic acid diethylamide;
25        (10.1) Salvinorin A;
26        (10.5) Salvia divinorum (meaning all parts of the plant

 

 

10000HB2534ham001- 8 -LRB100 08419 RLC 23080 a

1    presently classified botanically as Salvia divinorum,
2    whether growing or not, the seeds thereof, any extract from
3    any part of that plant, and every compound, manufacture,
4    salts, isomers, and salts of isomers whenever the existence
5    of such salts, isomers, and salts of isomers is possible
6    within the specific chemical designation, derivative,
7    mixture, or preparation of that plant, its seeds or
8    extracts);
9        (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
10        (12) Peyote (meaning all parts of the plant presently
11    classified botanically as Lophophora williamsii Lemaire,
12    whether growing or not, the seeds thereof, any extract from
13    any part of that plant, and every compound, manufacture,
14    salts, derivative, mixture, or preparation of that plant,
15    its seeds or extracts);
16        (13) N-ethyl-3-piperidyl benzilate (JB 318);
17        (14) N-methyl-3-piperidyl benzilate;
18        (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
19    (also known as N-hydroxy-alpha-methyl-
20    3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
21        (15) Parahexyl; some trade or other names:
22    3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
23    dibenzo (b,d) pyran; Synhexyl;
24        (16) Psilocybin;
25        (17) Psilocyn;
26        (18) Alpha-methyltryptamine (AMT);

 

 

10000HB2534ham001- 9 -LRB100 08419 RLC 23080 a

1        (19) 2,5-dimethoxyamphetamine
2    (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
3        (20) 4-bromo-2,5-dimethoxyamphetamine
4    (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
5    4-bromo-2,5-DMA);
6        (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
7    Some trade or other names: 2-(4-bromo-
8    2,5-dimethoxyphenyl)-1-aminoethane;
9    alpha-desmethyl DOB, 2CB, Nexus;
10        (21) 4-methoxyamphetamine
11    (4-methoxy-alpha-methylphenethylamine;
12    paramethoxyamphetamine; PMA);
13        (22) (Blank);
14        (23) Ethylamine analog of phencyclidine.
15    Some trade or other names:
16    N-ethyl-1-phenylcyclohexylamine,
17    (1-phenylcyclohexyl) ethylamine,
18    N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
19        (24) Pyrrolidine analog of phencyclidine. Some trade
20    or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
21    PHP;
22        (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
23        (26) 2,5-dimethoxy-4-ethylamphetamine
24    (another name: DOET);
25        (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
26    (another name: TCPy);

 

 

10000HB2534ham001- 10 -LRB100 08419 RLC 23080 a

1        (28) (Blank);
2        (29) Thiophene analog of phencyclidine (some trade
3    or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
4    2-thienyl analog of phencyclidine; TPCP; TCP);
5        (29.1) Benzothiophene analog of phencyclidine Some
6    trade or other names: BTCP or benocyclidine;
7        (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
8        (30) Bufotenine (some trade or other names:
9    3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
10    3-(2-dimethylaminoethyl)-5-indolol;
11    5-hydroxy-N,N-dimethyltryptamine;
12    N,N-dimethylserotonin; mappine);
13        (31) (Blank); 1-Pentyl-3-(1-naphthoyl)indole 
14    Some trade or other names: JWH-018; 
15        (32) (Blank); 1-Butyl-3-(1-naphthoyl)indole 
16    Some trade or other names: JWH-073;  
17        (33) (Blank); 1-[(5-fluoropentyl)-1H-indol-3-yl]- 
18    (2-iodophenyl)methanone 
19    Some trade or other names: AM-694;
20        (34) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5-
21    (2-methyloctan-2-yl)phenol 
22    Some trade or other names: CP 47,497 
23    and its C6, C8 and C9 homologs;
24        (34.5) (Blank); 2-[(1R,3S)-3-hydroxycyclohexyl]-5- 
25    (2-methyloctan-2-yl)phenol), where side chain n=5;  
26    and homologues where side chain n=4, 6, or 7; Some  

 

 

10000HB2534ham001- 11 -LRB100 08419 RLC 23080 a

1    trade or other names: CP 47,497; 
2        (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
3    (2-methyloctan-2-yl)-6a,7, 
4    10,10a-tetrahydrobenzo[c]chromen-1-ol
5    Some trade or other names: HU-210; 
6        (35.5)  (6aS,10aS)-9-(hydroxymethyl)-6,6- 
7    dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 
8    tetrahydrobenzo[c]chromen-1-ol, its isomers,  
9    salts, and salts of isomers; Some trade or other  
10    names: HU-210, Dexanabinol; 
11        (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
12    6,6-dimethyl-3-(2-methyloctan-2-yl)- 
13    6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
14    Some trade or other names: HU-211;
15        (37) (Blank); (2-methyl-1-propyl-1H-indol-
16    3-yl)-1-naphthalenyl-methanone 
17    Some trade or other names: JWH-015;
18        (38) (Blank); 4-methoxynaphthalen-1-yl-
19    (1-pentylindol-3-yl)methanone 
20    Some trade or other names: JWH-081;
21        (39) (Blank); 1-Pentyl-3-(4-methyl-1-naphthoyl)indole
22    Some trade or other names: JWH-122;
23        (40) (Blank); 2-(2-methylphenyl)-1-(1-pentyl-
24    1H-indol-3-yl)-ethanone 
25    Some trade or other names: JWH-251;
26        (41) (Blank); 1-(2-cyclohexylethyl)-3- 

 

 

10000HB2534ham001- 12 -LRB100 08419 RLC 23080 a

1    (2-methoxyphenylacetyl)indole 
2    Some trade or other names: RCS-8, BTW-8 and SR-18; 
3        (42)  Any compound structurally derived from 
4    3-(1-naphthoyl)indole or 1H-indol-3-yl- 
5    (1-naphthyl)methane by substitution at the 
6    nitrogen atom of the indole ring by alkyl, haloalkyl, 
7    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
8    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
9    or 2-(4-morpholinyl)ethyl whether or not further 
10    substituted in the indole ring to any extent, whether 
11    or not substituted in the naphthyl ring to any extent.
12    Examples of this structural class include, but are
13    not limited to, JWH-018, AM-2201, JWH-175, JWH-184,
14    and JWH-185;
15        (43)  Any compound structurally derived from 
16    3-(1-naphthoyl)pyrrole by substitution at the nitrogen 
17    atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, 
18    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
19    aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
20    or 2-(4-morpholinyl)ethyl, whether or not further 
21    substituted in the pyrrole ring to any extent, whether 
22    or not substituted in the naphthyl ring to any extent.
23    Examples of this structural class include, but are not
24    limited to, JWH-030, JWH-145, JWH-146, JWH-307, and
25    JWH-368; 
26        (44)  Any compound structurally derived from 

 

 

10000HB2534ham001- 13 -LRB100 08419 RLC 23080 a

1    1-(1-naphthylmethyl)indene by substitution 
2    at the 3-position of the indene ring by alkyl, haloalkyl, 
3    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
4    halide, alkyl aryl halide, 1-(N-methyl-
5    2-piperidinyl)methyl, or 2-(4-
6    morpholinyl)ethyl whether or not further substituted in
7    the indene ring to any extent, whether or not substituted
8    in the naphthyl ring to any extent. Examples of
9    this structural class include, but are not
10    limited to, JWH-176; 
11        (45)  Any compound structurally derived from 
12    3-phenylacetylindole by substitution at the 
13    nitrogen atom of the indole ring with alkyl, haloalkyl, 
14    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl
15    halide, alkyl aryl halide, 1-(N-methyl-2-
16    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
17    whether or not further substituted in the indole ring
18    to any extent, whether or not substituted in the phenyl
19    ring to any extent. Examples of this structural
20    class include, but are not limited to, JWH-167,
21    JWH-250, JWH-251, and RCS-8; 
22        (46) Any compound structurally derived from 
23    2-(3-hydroxycyclohexyl)phenol by substitution 
24    at the 5-position of the phenolic ring by alkyl, 
25    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
26    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 

 

 

10000HB2534ham001- 14 -LRB100 08419 RLC 23080 a

1    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
2    whether or not substituted in the cyclohexyl ring to any
3    extent. Examples of this structural class
4    include, but are not limited to, CP 47,
5    497 and its C8 homologue (cannabicyclohexanol); 
6        (46.1) Any compound structurally 
7    derived from Benzoylindoles: Any compound 
8    containing a 3-(benzoyl) indole structure with 
9    substitution at the nitrogen atom of the 
10    indole ring by an alkyl, haloalkyl, alkenyl, 
11    cycloalkylmethyl, cycloalkylethyl, 
12    aryl halide, alkyl aryl halide, 
13    1-(N-methyl-2-piperidinyl)methyl, 
14    or 2-(4-morpholinyl)ethyl group 
15    whether or not further substituted 
16    in the indole ring to any extent and 
17    whether or not substituted in the phenyl ring 
18    to any extent. Examples of this structural class 
19    include, but are not limited, to, AM-630, 
20    AM-2233, AM-694, Pravadoline (WIN 48,098), and RCS-4; 
21        (47) (Blank); 3,4-Methylenedioxymethcathinone 
22    Some trade or other names: Methylone; 
23        (48) (Blank); 3,4-Methyenedioxypyrovalerone 
24    Some trade or other names: MDPV; 
25        (49) (Blank); 4-Methylmethcathinone 
26    Some trade or other names: Mephedrone; 

 

 

10000HB2534ham001- 15 -LRB100 08419 RLC 23080 a

1        (50) (Blank); 4-methoxymethcathinone; 
2        (51) (Blank); 4-Fluoromethcathinone; 
3        (52) (Blank); 3-Fluoromethcathinone; 
4        (53)  2,5-Dimethoxy-4-(n)-propylthio- 
5    phenethylamine; 
6    Some trade or other names: 2C-T-7; 
7        (53.1) 4-ethyl-2,5-dimethoxyphenethylamine 
8    Some trade or other names: 2C-E; 
9        (53.2) 2,5-dimethoxy-4-methylphenethylamine 
10    Some trade or other names: 2C-D; 
11        (53.3) 4-chloro-2,5-dimethoxyphenethylamine 
12    Some trade or other names: 2C-C; 
13        (53.4) 4-iodo-2,5-dimethoxyphenethylamine 
14    Some trade or other names: 2C-I; 
15        (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine 
16    Some trade or other names: 2C-T-2; 
17        (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine 
18    Some trade or other names: 2C-T-4; 
19        (53.7) 2,5-dimethoxyphenethylamine 
20    Some trade or other names: 2C-H; 
21        (53.8) 2,5-dimethoxy-4-nitrophenethylamine 
22    Some trade or other names: 2C-N; 
23        (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine 
24    Some trade or other names: 2C-P; 
25        (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine 
26    Some trade or other names: 2C-G; 

 

 

10000HB2534ham001- 16 -LRB100 08419 RLC 23080 a

1        (53.11) The N-(2-methoxybenzyl) derivative of any 2C
2    phenethylamine referred to in subparagraphs (20.1), (53),
3    (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
4    (53.8), (53.9), and (53.10) including, but not limited to,
5    25I-NBOMe and 25C-NBOMe;
6        (54)  5-Methoxy-N,N-diisopropyltryptamine; 
7        (55) (Blank); Pentedrone;  
8        (56) (Blank); 4-iodo-2,5-dimethoxy-N-((2-methoxy 
9    phenyl)methyl)-benzeneethanamine 
10    (trade or other name: 25I-NBOMe); 
11        (57) (Blank); 4-chloro-2,5-dimethoxy- 
12    N-[(2-methoxyphenyl) methyl]-benzeneethanamine
13    (trade or other name: 25C-NBOMe); 
14        (58) (Blank); 4-bromo-2,5-dimethoxy 
15    -N-[(2-methoxyphenyl) methyl]-benzeneethanamine
16    (trade or other name: 25B-NBOMe); 
17        (59)  3-cyclopropoylindole with 
18    substitution at the nitrogen atom of the 
19    indole ring by alkyl, haloalkyl, alkenyl, 
20    cycloalkylmethyl, cycloalkylethyl, aryl 
21    halide, alkyl aryl halide, 
22    1-(N-methyl-2-piperidinyl)methyl, or 
23    2-(4-morpholinyl)ethyl, whether or not 
24    further substituted on the indole ring 
25    to any extent, whether or not substituted 
26    on the cyclopropyl ring to any extent: 

 

 

10000HB2534ham001- 17 -LRB100 08419 RLC 23080 a

1    including, but not limited to, XLR11, 
2    UR144, FUB-144; 
3        (60)  3-adamantoylindole with 
4    substitution at the nitrogen atom of the 
5    indole ring by alkyl, haloalkyl, alkenyl, 
6    cycloalkylmethyl, cycloalkylethyl, 
7    aryl halide, alkyl aryl halide, 
8    1-(N-methyl-2-piperidinyl)methyl, or 
9    2-(4-morpholinyl)ethyl, whether or not 
10    further substituted on the indole ring to 
11    any extent, whether or not substituted on 
12    the adamantyl ring to any extent: including, 
13    but not limited to, AB-001; 
14        (61)  N-(adamantyl)-indole-3-carboxamide 
15    with substitution at the nitrogen atom of the 
16    indole ring by alkyl, haloalkyl, alkenyl, 
17    cycloalkylmethyl, cycloalkylethyl, aryl halide, 
18    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, 
19    or 2-(4-morpholinyl)ethyl, whether or not further 
20    substituted on the indole ring to any extent, whether 
21    or not substituted on the adamantyl ring to any 
22    extent: including, but not limited to, 
23    APICA/2NE-1, STS-135; 
24        (62)  N-(adamantyl)-indazole-3-carboxamide 
25    with substitution at a nitrogen atom of the indazole 
26    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 

 

 

10000HB2534ham001- 18 -LRB100 08419 RLC 23080 a

1    cycloalkylethyl, aryl halide, alkyl aryl halide, 
2    1-(N-methyl-2-piperidinyl)methyl, or 
3    2-(4-morpholinyl)ethyl, whether or not further 
4    substituted on the indazole ring to any extent, 
5    whether or not substituted on the adamantyl 
6    ring to any extent: including, but not limited 
7    to, AKB48, 5F-AKB48; 
8        (63)  1H-indole-3-carboxylic acid 8-quinolinyl 
9    ester with substitution at the nitrogen atom of the 
10    indole ring by alkyl, haloalkyl, alkenyl, 
11    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
12    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
13    2-(4-morpholinyl)ethyl, whether or not further 
14    substituted on the indole ring to any extent, 
15    whether or not substituted on the quinoline ring 
16    to any extent: including, but not limited to, PB22, 
17    5F-PB22, FUB-PB-22; 
18        (64)  3-(1-naphthoyl)indazole with 
19    substitution at the nitrogen atom of the 
20    indazole ring by alkyl, haloalkyl, 
21    alkenyl, cycloalkylmethyl, cycloalkylethyl, 
22    aryl halide, alkyl aryl halide, 
23    1-(N-methyl-2-piperidinyl)methyl, or 
24    2-(4-morpholinyl)ethyl, whether or not further 
25    substituted on the indazole ring to any extent, 
26    whether or not substituted on the naphthyl ring 

 

 

10000HB2534ham001- 19 -LRB100 08419 RLC 23080 a

1    to any extent: including, but not limited to, 
2    THJ-018, THJ-2201; 
3        (65)  2-(1-naphthoyl)benzimidazole with 
4    substitution at the nitrogen atom of the benzimidazole 
5    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, 
6    cycloalkylethyl, aryl halide, alkyl aryl halide, 
7    1-(N-methyl-2-piperidinyl)methyl, or 
8    2-(4-morpholinyl)ethyl, whether or not further 
9    substituted on the benzimidazole ring to any extent, 
10    whether or not substituted on the naphthyl ring to 
11    any extent: including, but not limited to, FUBIMINA; 
12        (66)  N-(1-amino-3-methyl-1-oxobutan-2-yl) 
13    -1H-indazole-3-carboxamide with substitution on the 
14    nitrogen atom of the indazole ring by alkyl, 
15    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
16    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
17    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
18    whether or not further substituted on the indazole 
19    ring to any extent: including, but not limited to, 
20    AB-PINACA, AB-FUBINACA, AB-CHMINACA; 
21        (67)  N-(1-amino-3,3-dimethyl-1-oxobutan- 
22    2-yl)-1H-indazole-3-carboxamide with substitution 
23    on the nitrogen atom of the indazole ring by alkyl, 
24    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
25    aryl halide, alkyl aryl halide, 1-(N-methyl-2- 
26    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether 

 

 

10000HB2534ham001- 20 -LRB100 08419 RLC 23080 a

1    or not further substituted on the indazole ring to any 
2    extent: including, but not limited to, ADB-PINACA, 
3ADB-FUBINACA; 
4        (68)  N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)- 
5    1H-indole-3-carboxamide with substitution on the nitrogen 
6    atom of the indole ring by alkyl, haloalkyl, alkenyl, 
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl 
8    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 
9    2-(4-morpholinyl)ethyl, whether or not further 
10    substituted on the indole ring to any extent: 
11    including, but not limited to, ADBICA, 5F-ADBICA; 
12        (69)  N-(1-amino-3-methyl-1-oxobutan-2-yl)- 
13    1H-indole-3-carboxamide with substitution on the 
14    nitrogen atom of the indole ring by alkyl, haloalkyl, 
15    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
16    halide, alkyl aryl halide, 1-(N-methyl-2- 
17    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 
18    whether or not further substituted on the indole 
19    ring to any extent: including, but not limited 
20    to, ABICA, 5F-ABICA; 
21        (70)  Methyl 2-(1H-indazole-3-carboxamido)- 
22    3-methylbutanoate with substitution on the nitrogen 
23    atom of the indazole ring by alkyl, haloalkyl, 
24    alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl 
25    halide, alkyl aryl halide, 1-(N-methyl-2- 
26    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, 

 

 

10000HB2534ham001- 21 -LRB100 08419 RLC 23080 a

1    whether or not further substituted on the indazole 
2    ring to any extent: including, but not limited to, AMB, 
35F-AMB. 
4        (71) Methyl 2-(1H-indazole-3-carboxamido)
5    -3,3-dimethylbutanoate with substitution on the nitrogen
6    atom of the indazole ring by alkyl, haloalkyl, alkenyl,
7    cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
8    aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-
9    (4-morpholinyl)ethyl, whether or not further substituted
10    on the indazole ring to any extent: including, but not
11    limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; 
12        (72) Methyl 2-(1H-indole-3-carboxamido)-
13    3-methylbutanoate with substitution on the nitrogen atom
14    of the indole ring by alkyl, haloalkyl, alkenyl,
15    cycloalkylmethyl, cycloalkylethyl, aryl halide,
16    alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl,
17    or 2-(4-morpholinyl)ethyl, whether or not further
18    substituted on the indazole ring to any extent:
19    including, but not limited to, MMB018, MMB2201,
20    and AMB-CHMICA; 
21        (73) Methyl 2-(1H-indole-3-
22    carboxamido)-3,3-dimethylbutanoate with substitution
23    on the nitrogen atom of the indole ring by alkyl,
24    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
25    aryl halide, alkyl aryl halide, 1-(N-methyl-2-
26    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,

 

 

10000HB2534ham001- 22 -LRB100 08419 RLC 23080 a

1    whether or not further substituted on the
2    indazole ring to any extent: including, but
3    not limited to, MDMB-CHMICA; 
4        (74) N-(1-Amino-1-oxo-3-phenylpropan
5    -2-yl) -1H-indazole-3-carboxamide with
6    substitution on the nitrogen atom of the indazole
7    ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
8    cycloalkylethyl, aryl halide, alkyl aryl halide,
9    1-(N-methyl-2-piperidinyl)methyl, or 2-(4-
10    morpholinyl)ethyl, whether or not further
11    substituted on the indazole ring to any
12    extent: including, but not limited to, APP-CHMINACA,
13    5-fluoro-APP-PINACA; 
14        (75) N-(1-Amino-1-oxo-3-phenylpropan
15    -2-yl)-1H-indole-3-carboxamide with substitution on
16    the nitrogen atom of the indole ring by alkyl,
17    haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
18    aryl halide, alkyl aryl halide, 1-(N-methyl-2-
19    piperidinyl)methyl, or 2-(4-morpholinyl)ethyl,
20    whether or not further substituted on the indazole
21    ring to any extent: including, but not limited to,
22    APP-PICA and 5-fluoro-APP-PICA; 
23        (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
24    4-AcO-DMT;
25        (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: Trade
26    name 5-MeO-MIPT;

 

 

10000HB2534ham001- 23 -LRB100 08419 RLC 23080 a

1        (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
2        (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
3        (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
4        (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
5    (4-HO-MiPT); 
6        (82) Fluorophenylpiperazine;
7        (83) Methoxetamine;
8        (84) 1-(Ethylamino)-2-phenylpropan-2-
9    one (iso-ethcathinone). 
10    (e) Unless specifically excepted or unless listed in
11another schedule, any material, compound, mixture, or
12preparation which contains any quantity of the following
13substances having a depressant effect on the central nervous
14system, including its salts, isomers, and salts of isomers
15whenever the existence of such salts, isomers, and salts of
16isomers is possible within the specific chemical designation:
17        (1) mecloqualone;
18        (2) methaqualone; and
19        (3) gamma hydroxybutyric acid.
20    (f) Unless specifically excepted or unless listed in
21another schedule, any material, compound, mixture, or
22preparation which contains any quantity of the following
23substances having a stimulant effect on the central nervous
24system, including its salts, isomers, and salts of isomers:
25        (1) Fenethylline;
26        (2) N-ethylamphetamine;

 

 

10000HB2534ham001- 24 -LRB100 08419 RLC 23080 a

1        (3) Aminorex (some other names:
2    2-amino-5-phenyl-2-oxazoline; aminoxaphen;
3    4-5-dihydro-5-phenyl-2-oxazolamine) and its
4    salts, optical isomers, and salts of optical isomers;
5        (4) Methcathinone (some other names:
6    2-methylamino-1-phenylpropan-1-one;
7    Ephedrone; 2-(methylamino)-propiophenone;
8    alpha-(methylamino)propiophenone; N-methylcathinone;
9    methycathinone; Monomethylpropion; UR 1431) and its
10    salts, optical isomers, and salts of optical isomers;
11        (5) Cathinone (some trade or other names:
12    2-aminopropiophenone; alpha-aminopropiophenone;
13    2-amino-1-phenyl-propanone; norephedrone);
14        (6) N,N-dimethylamphetamine (also known as:
15    N,N-alpha-trimethyl-benzeneethanamine;
16    N,N-alpha-trimethylphenethylamine);
17        (7) (+ or -) cis-4-methylaminorex  ((+ or -) cis-
18    4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
19        (8) 3,4-Methylenedioxypyrovalerone (MDPV); .
20        (9) Halogenated amphetamines and
21    methamphetamines  any compound derived from either
22    amphetamine or methamphetamine through the substitution
23    of a halogen on the phenyl ring, including, but not
24    limited to, 2-fluoroamphetamine, 3-
25    fluoroamphetamine and 4-fluoroamphetamine; 
26        (10) Aminopropylbenzofuran (APB):

 

 

10000HB2534ham001- 25 -LRB100 08419 RLC 23080 a

1    including 4-(2-Aminopropyl) benzofuran, 5-
2    (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
3    benzofuran, and 7-(2-Aminopropyl) benzofuran; 
4        (11) Aminopropyldihydrobenzofuran (APDB):
5    including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
6    5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
7    6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
8    and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; 
9        (12) Methylaminopropylbenzofuran
10    (MAPB): including 4-(2-methylaminopropyl)
11    benzofuran, 5-(2-methylaminopropyl)benzofuran,
12    6-(2-methylaminopropyl)benzofuran
13    and 7-(2-methylaminopropyl)benzofuran. 
14    (g) Temporary listing of substances subject to emergency
15scheduling. Any material, compound, mixture, or preparation
16that contains any quantity of the following substances:
17        (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
18    (benzylfentanyl), its optical isomers, isomers, salts,
19    and salts of isomers;
20        (2) N-[1(2-thienyl)
21   methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
22   its optical isomers, salts, and salts of isomers.
23    (h) Synthetic cathinones. Unless specifically excepted,
24any chemical compound which is not approved by the United
25States Food and Drug Administration or, if approved, is not
26dispensed or possessed in accordance with State or federal law,

 

 

10000HB2534ham001- 26 -LRB100 08419 RLC 23080 a

1not including bupropion, structurally derived from
22-aminopropan-1-one by substitution at the 1-position with
3either phenyl, naphthyl, or thiophene ring systems, whether or
4not the compound is further modified in one or more of the
5following ways:
6        (1) by substitution in the ring system to 
7    any extent with alkyl, alkylenedioxy, alkoxy, 
8    haloalkyl, hydroxyl, or halide substituents, whether 
9    or not further substituted in the ring system 
10    by one or more other univalent substituents. 
11    Examples of this class include, but are not 
12    limited to, 3,4-Methylenedioxycathinone 
13    (bk-MDA); 
14        (2) by substitution at the 3-position 
15    with an acyclic alkyl substituent. Examples of 
16    this class include, but are not limited to, 
17    2-methylamino-1-phenylbutan-1-one 
18    (buphedrone); or 
19        (3) by substitution at the 2-amino nitrogen 
20    atom with alkyl, dialkyl, benzyl, or methoxybenzyl 
21    groups, or by inclusion of the 2-amino nitrogen atom 
22    in a cyclic structure. Examples of this class include, 
23    but are not limited to, Dimethylcathinone, Ethcathinone, 
24    and a-Pyrrolidinopropiophenone (a-PPP). 
25(Source: P.A. 98-987, eff. 1-1-15; 99-371, eff. 1-1-16; revised
2610-25-16.)
 

 

 

10000HB2534ham001- 27 -LRB100 08419 RLC 23080 a

1    (720 ILCS 570/206)  (from Ch. 56 1/2, par. 1206)
2    Sec. 206. (a) The controlled substances listed in this
3Section are included in Schedule II.
4    (b) Unless specifically excepted or unless listed in
5another schedule, any of the following substances whether
6produced directly or indirectly by extraction from substances
7of vegetable origin, or independently by means of chemical
8synthesis, or by combination of extraction and chemical
9synthesis:
10        (1) Opium and opiates, and any salt, compound,
11    derivative or preparation of opium or opiate, excluding
12    apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
13    nalmefene, naloxone, and naltrexone, and their respective
14    salts, but including the following:
15            (i) Raw Opium;
16            (ii) Opium extracts;
17            (iii) Opium fluid extracts;
18            (iv) Powdered opium;
19            (v) Granulated opium;
20            (vi) Tincture of opium;
21            (vii) Codeine;
22            (viii) Ethylmorphine;
23            (ix) Etorphine Hydrochloride;
24            (x) Hydrocodone;
25            (xi) Hydromorphone;

 

 

10000HB2534ham001- 28 -LRB100 08419 RLC 23080 a

1            (xii) Metopon;
2            (xiii) Morphine;
3            (xiii.5) 6-Monoacetylmorphine;
4            (xiv) Oxycodone;
5            (xv) Oxymorphone;
6            (xv.5) Tapentadol;
7            (xvi) Thebaine;
8            (xvii) Thebaine-derived butorphanol.
9            (xviii) Methorphan Dextromethorphan, except drug
10        products containing dextromethorphan that may be
11        dispensed pursuant to a prescription order of a
12        practitioner and are sold in compliance with the safety
13        and labeling standards as set forth by the United
14        States Food and Drug Administration, or drug products
15        containing dextromethorphan that are sold in solid,
16        tablet, liquid, capsule, powder, thin film, or gel form
17        and which are formulated, packaged, and sold in dosages
18        and concentrations for use as an over-the-counter drug
19        product. For the purposes of this Section,
20        "over-the-counter drug product" means a drug that is
21        available to consumers without a prescription and sold
22        in compliance with the safety and labeling standards as
23        set forth by the United States Food and Drug
24        Administration.
25        (2) Any salt, compound, isomer, derivative or
26    preparation thereof which is chemically equivalent or

 

 

10000HB2534ham001- 29 -LRB100 08419 RLC 23080 a

1    identical with any of the substances referred to in
2    subparagraph (1), but not including the isoquinoline
3    alkaloids of opium;
4        (3) Opium poppy and poppy straw;
5        (4) Coca leaves and any salt, compound, isomer, salt of
6    an isomer, derivative, or preparation of coca leaves
7    including cocaine or ecgonine, and any salt, compound,
8    isomer, derivative, or preparation thereof which is
9    chemically equivalent or identical with any of these
10    substances, but not including decocainized coca leaves or
11    extractions of coca leaves which do not contain cocaine or
12    ecgonine (for the purpose of this paragraph, the term
13    "isomer" includes optical, positional and geometric
14    isomers);
15        (5) Concentrate of poppy straw (the crude extract of
16    poppy straw in either liquid, solid or powder form which
17    contains the phenanthrine alkaloids of the opium poppy).
18    (c) Unless specifically excepted or unless listed in
19another schedule any of the following opiates, including their
20isomers, esters, ethers, salts, and salts of isomers, whenever
21the existence of these isomers, esters, ethers and salts is
22possible within the specific chemical designation, dextrorphan
23excepted:
24        (1) Alfentanil;
25        (1.1) Carfentanil;
26        (1.2) Thiafentanyl;

 

 

10000HB2534ham001- 30 -LRB100 08419 RLC 23080 a

1        (2) Alphaprodine;
2        (3) Anileridine;
3        (4) Bezitramide;
4        (5) Bulk Dextropropoxyphene (non-dosage forms);
5        (6) Dihydrocodeine;
6        (7) Diphenoxylate;
7        (8) Fentanyl;
8        (9) Sufentanil;
9        (9.5) Remifentanil;
10        (10) Isomethadone;
11        (11) (Blank); Levomethorphan;
12        (12) Levorphanol (Levorphan);
13        (13) Metazocine;
14        (14) Methadone;
15        (15) Methadone-Intermediate,
16    4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
17        (16) Moramide-Intermediate,
18    2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
19    acid;
20        (17) Pethidine (meperidine);
21        (18) Pethidine-Intermediate-A,
22    4-cyano-1-methyl-4-phenylpiperidine;
23        (19) Pethidine-Intermediate-B,
24    ethyl-4-phenylpiperidine-4-carboxylate;
25        (20) Pethidine-Intermediate-C,
26    1-methyl-4-phenylpiperidine-4-carboxylic acid;

 

 

10000HB2534ham001- 31 -LRB100 08419 RLC 23080 a

1        (21) Phenazocine;
2        (22) Piminodine;
3        (23) Racemethorphan;
4        (24) (Blank); Racemorphan;
5        (25) Levo-alphacetylmethadol (some other names:
6    levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
7    (d) Unless specifically excepted or unless listed in
8another schedule, any material, compound, mixture, or
9preparation which contains any quantity of the following
10substances having a stimulant effect on the central nervous
11system:
12        (1) Amphetamine, its salts, optical isomers, and salts
13    of its optical isomers;
14        (2) Methamphetamine, its salts, isomers, and salts of
15    its isomers;
16        (3) Phenmetrazine and its salts;
17        (4) Methylphenidate;
18        (5) Lisdexamfetamine.
19    (e) Unless specifically excepted or unless listed in
20another schedule, any material, compound, mixture, or
21preparation which contains any quantity of the following
22substances having a depressant effect on the central nervous
23system, including its salts, isomers, and salts of isomers
24whenever the existence of such salts, isomers, and salts of
25isomers is possible within the specific chemical designation:
26        (1) Amobarbital;

 

 

10000HB2534ham001- 32 -LRB100 08419 RLC 23080 a

1        (2) Secobarbital;
2        (3) Pentobarbital;
3        (4) Pentazocine;
4        (5) Phencyclidine;
5        (6) Gluthethimide;
6        (7) (Blank).
7    (f) Unless specifically excepted or unless listed in
8another schedule, any material, compound, mixture, or
9preparation which contains any quantity of the following
10substances:
11        (1) Immediate precursor to amphetamine and
12    methamphetamine:
13            (i) Phenylacetone
14        Some trade or other names: phenyl-2-propanone;
15        P2P; benzyl methyl ketone; methyl benzyl ketone.
16        (2) Immediate precursors to phencyclidine:
17            (i) 1-phenylcyclohexylamine;
18            (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
19        (3) Nabilone.
20(Source: P.A. 97-334, eff. 1-1-12.)
 
21    (720 ILCS 570/208)  (from Ch. 56 1/2, par. 1208)
22    Sec. 208. (a) The controlled substances listed in this
23Section are included in Schedule III.
24    (b) Unless specifically excepted or unless listed in
25another schedule, any material, compound, mixture, or

 

 

10000HB2534ham001- 33 -LRB100 08419 RLC 23080 a

1preparation which contains any quantity of the following
2substances having a stimulant effect on the central nervous
3system, including its salts, isomers (whether optical
4position, or geometric), and salts of such isomers whenever the
5existence of such salts, isomers, and salts of isomers is
6possible within the specific chemical designation;
7        (1) Those compounds, mixtures, or preparations in
8    dosage unit form containing any stimulant substances
9    listed in Schedule II which compounds, mixtures, or
10    preparations were listed on August 25, 1971, as excepted
11    compounds under Title 21, Code of Federal Regulations,
12    Section 308.32, and any other drug of the quantitative
13    composition shown in that list for those drugs or which is
14    the same except that it contains a lesser quantity of
15    controlled substances;
16        (2) Benzphetamine;
17        (3) Chlorphentermine;
18        (4) Clortermine;
19        (5) Phendimetrazine.
20    (c) Unless specifically excepted or unless listed in
21another schedule, any material, compound, mixture, or
22preparation which contains any quantity of the following
23substances having a potential for abuse associated with a
24depressant effect on the central nervous system:
25        (1) Any compound, mixture, or preparation containing
26    amobarbital, secobarbital, pentobarbital or any salt

 

 

10000HB2534ham001- 34 -LRB100 08419 RLC 23080 a

1    thereof and one or more other active medicinal ingredients
2    which are not listed in any schedule;
3        (2) Any suppository dosage form containing
4    amobarbital, secobarbital, pentobarbital or any salt of
5    any of these drugs and approved by the Federal Food and
6    Drug Administration for marketing only as a suppository;
7        (3) Any substance which contains any quantity of a
8    derivative of barbituric acid, or any salt thereof:
9        (3.1) Aprobarbital;
10        (3.2) Butabarbital (secbutabarbital);
11        (3.3) Butalbital;
12        (3.4) Butobarbital (butethal);
13        (4) Chlorhexadol;
14        (5) Methyprylon;
15        (6) Sulfondiethylmethane;
16        (7) Sulfonethylmethane;
17        (8) Sulfonmethane;
18        (9) Lysergic acid;
19        (10) Lysergic acid amide;
20        (10.1) Tiletamine or zolazepam or both, or any salt of
21    either of them.
22    Some trade or other names for a tiletamine-zolazepam
23    combination product: Telazol.
24    Some trade or other names for Tiletamine:
25    2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
26    Some trade or other names for zolazepam:

 

 

10000HB2534ham001- 35 -LRB100 08419 RLC 23080 a

1    4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
2    [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
3        (11) Any material, compound, mixture or preparation
4    containing not more than 12.5 milligrams of pentazocine or
5    any of its salts, per 325 milligrams of aspirin;
6        (12) Any material, compound, mixture or preparation
7    containing not more than 12.5 milligrams of pentazocine or
8    any of its salts, per 325 milligrams of acetaminophen;
9        (13) Any material, compound, mixture or preparation
10    containing not more than 50 milligrams of pentazocine or
11    any of its salts plus naloxone HCl USP 0.5 milligrams, per
12    dosage unit;
13        (14) Ketamine;
14        (15) Thiopental.
15    (d) Nalorphine.
16    (d.5) Buprenorphine.
17    (e) Unless specifically excepted or unless listed in
18another schedule, any material, compound, mixture, or
19preparation containing limited quantities of any of the
20following narcotic drugs, or their salts calculated as the free
21anhydrous base or alkaloid, as set forth below:
22        (1) not more than 1.8 grams of codeine per 100
23    milliliters or not more than 90 milligrams per dosage unit,
24    with an equal or greater quantity of an isoquinoline
25    alkaloid of opium;
26        (2) not more than 1.8 grams of codeine per 100

 

 

10000HB2534ham001- 36 -LRB100 08419 RLC 23080 a

1    milliliters or not more than 90 milligrams per dosage unit,
2    with one or more active non-narcotic ingredients in
3    recognized therapeutic amounts;
4        (3) (blank); not more than 300 milligrams of
5    dihydrocodeinone per 100 milliliters or not more than 15
6    milligrams per dosage unit, with a fourfold or greater
7    quantity of an isoquinoline alkaloid of opium;
8        (4) (blank); not more than 300 milligrams of
9    dihydrocodeinone per 100 milliliters or not more than 15
10    milligrams per dosage unit, with one or more active,
11    non-narcotic ingredients in recognized therapeutic
12    amounts;
13        (5) not more than 1.8 grams of dihydrocodeine per 100
14    milliliters or not more than 90 milligrams per dosage unit,
15    with one or more active, non-narcotic ingredients in
16    recognized therapeutic amounts;
17        (6) not more than 300 milligrams of ethylmorphine per
18    100 milliliters or not more than 15 milligrams per dosage
19    unit, with one or more active, non-narcotic ingredients in
20    recognized therapeutic amounts;
21        (7) not more than 500 milligrams of opium per 100
22    milliliters or per 100 grams, or not more than 25
23    milligrams per dosage unit, with one or more active,
24    non-narcotic ingredients in recognized therapeutic
25    amounts;
26        (8) not more than 50 milligrams of morphine per 100

 

 

10000HB2534ham001- 37 -LRB100 08419 RLC 23080 a

1    milliliters or per 100 grams with one or more active,
2    non-narcotic ingredients in recognized therapeutic
3    amounts.
4    (f) Anabolic steroids, except the following anabolic
5steroids that are exempt:
6        (1) Androgyn L.A.;
7        (2) Andro-Estro 90-4;
8        (3) depANDROGYN;
9        (4) DEPO-T.E.;
10        (5) depTESTROGEN;
11        (6) Duomone;
12        (7) DURATESTRIN;
13        (8) DUO-SPAN II;
14        (9) Estratest;
15        (10) Estratest H.S.;
16        (11) PAN ESTRA TEST;
17        (12) Premarin with Methyltestosterone;
18        (13) TEST-ESTRO Cypionates;
19        (14) Testosterone Cyp 50 Estradiol Cyp 2;
20        (15) Testosterone Cypionate-Estradiol Cypionate
21    injection; and
22        (16) Testosterone Enanthate-Estradiol Valerate
23    injection.
24    (g) Hallucinogenic substances.
25        (1) Dronabinol (synthetic) in sesame oil and
26    encapsulated in a soft gelatin capsule in a U.S. Food and

 

 

10000HB2534ham001- 38 -LRB100 08419 RLC 23080 a

1    Drug Administration approved product. Some other names for
2    dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
3    6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
4    (-)-delta-9-(trans)-tetrahydrocannabinol.
5        (2) (Reserved).
6    (h) The Department may except by rule any compound,
7mixture, or preparation containing any stimulant or depressant
8substance listed in subsection (b) from the application of all
9or any part of this Act if the compound, mixture, or
10preparation contains one or more active medicinal ingredients
11not having a stimulant or depressant effect on the central
12nervous system, and if the admixtures are included therein in
13combinations, quantity, proportion, or concentration that
14vitiate the potential for abuse of the substances which have a
15stimulant or depressant effect on the central nervous system.
16(Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10;
1797-334, eff. 1-1-12.)
 
18    (720 ILCS 570/401)  (from Ch. 56 1/2, par. 1401)
19    Sec. 401. Manufacture or delivery, or possession with
20intent to manufacture or deliver, a controlled substance, a
21counterfeit substance, or controlled substance analog. Except
22as authorized by this Act, it is unlawful for any person
23knowingly to manufacture or deliver, or possess with intent to
24manufacture or deliver, a controlled substance other than
25methamphetamine and other than bath salts as defined in the

 

 

10000HB2534ham001- 39 -LRB100 08419 RLC 23080 a

1Bath Salts Prohibition Act sold or offered for sale in a retail
2mercantile establishment as defined in Section 16-0.1 of the
3Criminal Code of 2012, a counterfeit substance, or a controlled
4substance analog. A violation of this Act with respect to each
5of the controlled substances listed herein constitutes a single
6and separate violation of this Act. For purposes of this
7Section, "controlled substance analog" or "analog" means a
8substance, other than a controlled substance, which is not
9approved by the United States Food and Drug Administration or,
10if approved, is not dispensed or possessed in accordance with
11State or federal law, and that has a chemical structure
12substantially similar to that of a controlled substance in
13Schedule I or II, or that was specifically designed to produce
14an effect substantially similar to that of a controlled
15substance in Schedule I or II. Examples of chemical classes in
16which controlled substance analogs are found include, but are
17not limited to, the following: phenethylamines, N-substituted
18piperidines, morphinans, ecgonines, quinazolinones,
19substituted indoles, and arylcycloalkylamines. For purposes of
20this Act, a controlled substance analog shall be treated in the
21same manner as the controlled substance to which it is
22substantially similar.
23    (a) Any person who violates this Section with respect to
24the following amounts of controlled or counterfeit substances
25or controlled substance analogs, notwithstanding any of the
26provisions of subsections (c), (d), (e), (f), (g) or (h) to the

 

 

10000HB2534ham001- 40 -LRB100 08419 RLC 23080 a

1contrary, is guilty of a Class X felony and shall be sentenced
2to a term of imprisonment as provided in this subsection (a)
3and fined as provided in subsection (b):
4        (1) (A) not less than 6 years and not more than 30
5        years with respect to 15 grams or more but less than
6        100 grams of a substance containing heroin, or an
7        analog thereof;
8            (B) not less than 9 years and not more than 40
9        years with respect to 100 grams or more but less than
10        400 grams of a substance containing heroin, or an
11        analog thereof;
12            (C) not less than 12 years and not more than 50
13        years with respect to 400 grams or more but less than
14        900 grams of a substance containing heroin, or an
15        analog thereof;
16            (D) not less than 15 years and not more than 60
17        years with respect to 900 grams or more of any
18        substance containing heroin, or an analog thereof;
19        (1.5) (A) not less than 6 years and not more than 30
20        years with respect to 15 grams or more but less than
21        100 grams of a substance containing fentanyl, or an
22        analog thereof;
23            (B) not less than 9 years and not more than 40
24        years with respect to 100 grams or more but less than
25        400 grams of a substance containing fentanyl, or an
26        analog thereof;

 

 

10000HB2534ham001- 41 -LRB100 08419 RLC 23080 a

1            (C) not less than 12 years and not more than 50
2        years with respect to 400 grams or more but less than
3        900 grams of a substance containing fentanyl, or an
4        analog thereof;
5            (D) not less than 15 years and not more than 60
6        years with respect to 900 grams or more of a substance
7        containing fentanyl, or an analog thereof;
8        (2) (A) not less than 6 years and not more than 30
9        years with respect to 15 grams or more but less than
10        100 grams of a substance containing cocaine, or an
11        analog thereof;
12            (B) not less than 9 years and not more than 40
13        years with respect to 100 grams or more but less than
14        400 grams of a substance containing cocaine, or an
15        analog thereof;
16            (C) not less than 12 years and not more than 50
17        years with respect to 400 grams or more but less than
18        900 grams of a substance containing cocaine, or an
19        analog thereof;
20            (D) not less than 15 years and not more than 60
21        years with respect to 900 grams or more of any
22        substance containing cocaine, or an analog thereof;
23        (3) (A) not less than 6 years and not more than 30
24        years with respect to 15 grams or more but less than
25        100 grams of a substance containing morphine, or an
26        analog thereof;

 

 

10000HB2534ham001- 42 -LRB100 08419 RLC 23080 a

1            (B) not less than 9 years and not more than 40
2        years with respect to 100 grams or more but less than
3        400 grams of a substance containing morphine, or an
4        analog thereof;
5            (C) not less than 12 years and not more than 50
6        years with respect to 400 grams or more but less than
7        900 grams of a substance containing morphine, or an
8        analog thereof;
9            (D) not less than 15 years and not more than 60
10        years with respect to 900 grams or more of a substance
11        containing morphine, or an analog thereof;
12        (4) 200 grams or more of any substance containing
13    peyote, or an analog thereof;
14        (5) 200 grams or more of any substance containing a
15    derivative of barbituric acid or any of the salts of a
16    derivative of barbituric acid, or an analog thereof;
17        (6) 200 grams or more of any substance containing
18    amphetamine or any salt of an optical isomer of
19    amphetamine, or an analog thereof;
20        (6.5) (blank);
21        (6.6) (blank);
22        (7) (A) not less than 6 years and not more than 30
23        years with respect to: (i) 15 grams or more but less
24        than 100 grams of a substance containing lysergic acid
25        diethylamide (LSD), or an analog thereof, or (ii) 15 or
26        more objects or 15 or more segregated parts of an

 

 

10000HB2534ham001- 43 -LRB100 08419 RLC 23080 a

1        object or objects but less than 200 objects or 200
2        segregated parts of an object or objects containing in
3        them or having upon them any amounts of any substance
4        containing lysergic acid diethylamide (LSD), or an
5        analog thereof;
6            (B) not less than 9 years and not more than 40
7        years with respect to: (i) 100 grams or more but less
8        than 400 grams of a substance containing lysergic acid
9        diethylamide (LSD), or an analog thereof, or (ii) 200
10        or more objects or 200 or more segregated parts of an
11        object or objects but less than 600 objects or less
12        than 600 segregated parts of an object or objects
13        containing in them or having upon them any amount of
14        any substance containing lysergic acid diethylamide
15        (LSD), or an analog thereof;
16            (C) not less than 12 years and not more than 50
17        years with respect to: (i) 400 grams or more but less
18        than 900 grams of a substance containing lysergic acid
19        diethylamide (LSD), or an analog thereof, or (ii) 600
20        or more objects or 600 or more segregated parts of an
21        object or objects but less than 1500 objects or 1500
22        segregated parts of an object or objects containing in
23        them or having upon them any amount of any substance
24        containing lysergic acid diethylamide (LSD), or an
25        analog thereof;
26            (D) not less than 15 years and not more than 60

 

 

10000HB2534ham001- 44 -LRB100 08419 RLC 23080 a

1        years with respect to: (i) 900 grams or more of any
2        substance containing lysergic acid diethylamide (LSD),
3        or an analog thereof, or (ii) 1500 or more objects or
4        1500 or more segregated parts of an object or objects
5        containing in them or having upon them any amount of a
6        substance containing lysergic acid diethylamide (LSD),
7        or an analog thereof;
8        (7.5) (A) not less than 6 years and not more than 30
9        years with respect to: (i) 15 grams or more but less
10        than 100 grams of a substance listed in paragraph (1),
11        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12        (21), (25), or (26) of subsection (d) of Section 204,
13        or an analog or derivative thereof, or (ii) 15 or more
14        pills, tablets, caplets, capsules, or objects but less
15        than 200 pills, tablets, caplets, capsules, or objects
16        containing in them or having upon them any amounts of
17        any substance listed in paragraph (1), (2), (2.1),
18        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
19        (26) of subsection (d) of Section 204, or an analog or
20        derivative thereof;
21            (B) not less than 9 years and not more than 40
22        years with respect to: (i) 100 grams or more but less
23        than 400 grams of a substance listed in paragraph (1),
24        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
25        (21), (25), or (26) of subsection (d) of Section 204,
26        or an analog or derivative thereof, or (ii) 200 or more

 

 

10000HB2534ham001- 45 -LRB100 08419 RLC 23080 a

1        pills, tablets, caplets, capsules, or objects but less
2        than 600 pills, tablets, caplets, capsules, or objects
3        containing in them or having upon them any amount of
4        any substance listed in paragraph (1), (2), (2.1),
5        (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or
6        (26) of subsection (d) of Section 204, or an analog or
7        derivative thereof;
8            (C) not less than 12 years and not more than 50
9        years with respect to: (i) 400 grams or more but less
10        than 900 grams of a substance listed in paragraph (1),
11        (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
12        (21), (25), or (26) of subsection (d) of Section 204,
13        or an analog or derivative thereof, or (ii) 600 or more
14        pills, tablets, caplets, capsules, or objects but less
15        than 1,500 pills, tablets, caplets, capsules, or
16        objects containing in them or having upon them any
17        amount of any substance listed in paragraph (1), (2),
18        (2.1), (2.2), (3), (14.1), (19), (20), (20.1), (21),
19        (25), or (26) of subsection (d) of Section 204, or an
20        analog or derivative thereof;
21            (D) not less than 15 years and not more than 60
22        years with respect to: (i) 900 grams or more of any
23        substance listed in paragraph (1), (2), (2.1), (2.2),
24        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
25        subsection (d) of Section 204, or an analog or
26        derivative thereof, or (ii) 1,500 or more pills,

 

 

10000HB2534ham001- 46 -LRB100 08419 RLC 23080 a

1        tablets, caplets, capsules, or objects containing in
2        them or having upon them any amount of a substance
3        listed in paragraph (1), (2), (2.1), (2.2), (3),
4        (14.1), (19), (20), (20.1), (21), (25), or (26) of
5        subsection (d) of Section 204, or an analog or
6        derivative thereof;
7        (8) 30 grams or more of any substance containing
8    pentazocine or any of the salts, isomers and salts of
9    isomers of pentazocine, or an analog thereof;
10        (9) 30 grams or more of any substance containing
11    methaqualone or any of the salts, isomers and salts of
12    isomers of methaqualone, or an analog thereof;
13        (10) 30 grams or more of any substance containing
14    phencyclidine or any of the salts, isomers and salts of
15    isomers of phencyclidine (PCP), or an analog thereof;
16        (10.5) 30 grams or more of any substance containing
17    ketamine or any of the salts, isomers and salts of isomers
18    of ketamine, or an analog thereof;
19        (10.6) 100 grams or more of any substance containing
20    hydrocodone, or any of the salts, isomers and salts of
21    isomers of hydrocodone, or an analog thereof;
22        (10.7) (blank); 100 grams or more of any substance
23    containing dihydrocodeinone, or any of the salts, isomers
24    and salts of isomers of dihydrocodeinone, or an analog
25    thereof;
26        (10.8) 100 grams or more of any substance containing

 

 

10000HB2534ham001- 47 -LRB100 08419 RLC 23080 a

1    dihydrocodeine, or any of the salts, isomers and salts of
2    isomers of dihydrocodeine, or an analog thereof;
3        (10.9) 100 grams or more of any substance containing
4    oxycodone, or any of the salts, isomers and salts of
5    isomers of oxycodone, or an analog thereof;
6        (11) 200 grams or more of any substance containing any
7    other controlled substance classified in Schedules I or II,
8    or an analog thereof, which is not otherwise included in
9    this subsection.
10    (b) Any person sentenced with respect to violations of
11paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
12involving 100 grams or more of the controlled substance named
13therein, may in addition to the penalties provided therein, be
14fined an amount not more than $500,000 or the full street value
15of the controlled or counterfeit substance or controlled
16substance analog, whichever is greater. The term "street value"
17shall have the meaning ascribed in Section 110-5 of the Code of
18Criminal Procedure of 1963. Any person sentenced with respect
19to any other provision of subsection (a), may in addition to
20the penalties provided therein, be fined an amount not to
21exceed $500,000.
22    (b-1) Excluding violations of this Act when the controlled
23substance is fentanyl, any person sentenced to a term of
24imprisonment with respect to violations of Section 401, 401.1,
25405, 405.1, 405.2, or 407, when the substance containing the
26controlled substance contains any amount of fentanyl, 3 years

 

 

10000HB2534ham001- 48 -LRB100 08419 RLC 23080 a

1shall be added to the term of imprisonment imposed by the
2court, and the maximum sentence for the offense shall be
3increased by 3 years.
4    (c) Any person who violates this Section with regard to the
5following amounts of controlled or counterfeit substances or
6controlled substance analogs, notwithstanding any of the
7provisions of subsections (a), (b), (d), (e), (f), (g) or (h)
8to the contrary, is guilty of a Class 1 felony. The fine for
9violation of this subsection (c) shall not be more than
10$250,000:
11        (1) 1 gram or more but less than 15 grams of any
12    substance containing heroin, or an analog thereof;
13        (1.5) 1 gram or more but less than 15 grams of any
14    substance containing fentanyl, or an analog thereof;
15        (2) 1 gram or more but less than 15 grams of any
16    substance containing cocaine, or an analog thereof;
17        (3) 10 grams or more but less than 15 grams of any
18    substance containing morphine, or an analog thereof;
19        (4) 50 grams or more but less than 200 grams of any
20    substance containing peyote, or an analog thereof;
21        (5) 50 grams or more but less than 200 grams of any
22    substance containing a derivative of barbituric acid or any
23    of the salts of a derivative of barbituric acid, or an
24    analog thereof;
25        (6) 50 grams or more but less than 200 grams of any
26    substance containing amphetamine or any salt of an optical

 

 

10000HB2534ham001- 49 -LRB100 08419 RLC 23080 a

1    isomer of amphetamine, or an analog thereof;
2        (6.5) (blank);
3        (7) (i) 5 grams or more but less than 15 grams of any
4    substance containing lysergic acid diethylamide (LSD), or
5    an analog thereof, or (ii) more than 10 objects or more
6    than 10 segregated parts of an object or objects but less
7    than 15 objects or less than 15 segregated parts of an
8    object containing in them or having upon them any amount of
9    any substance containing lysergic acid diethylamide (LSD),
10    or an analog thereof;
11        (7.5) (i) 5 grams or more but less than 15 grams of any
12    substance listed in paragraph (1), (2), (2.1), (2.2), (3),
13    (14.1), (19), (20), (20.1), (21), (25), or (26) of
14    subsection (d) of Section 204, or an analog or derivative
15    thereof, or (ii) more than 10 pills, tablets, caplets,
16    capsules, or objects but less than 15 pills, tablets,
17    caplets, capsules, or objects containing in them or having
18    upon them any amount of any substance listed in paragraph
19    (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1),
20    (21), (25), or (26) of subsection (d) of Section 204, or an
21    analog or derivative thereof;
22        (8) 10 grams or more but less than 30 grams of any
23    substance containing pentazocine or any of the salts,
24    isomers and salts of isomers of pentazocine, or an analog
25    thereof;
26        (9) 10 grams or more but less than 30 grams of any

 

 

10000HB2534ham001- 50 -LRB100 08419 RLC 23080 a

1    substance containing methaqualone or any of the salts,
2    isomers and salts of isomers of methaqualone, or an analog
3    thereof;
4        (10) 10 grams or more but less than 30 grams of any
5    substance containing phencyclidine or any of the salts,
6    isomers and salts of isomers of phencyclidine (PCP), or an
7    analog thereof;
8        (10.5) 10 grams or more but less than 30 grams of any
9    substance containing ketamine or any of the salts, isomers
10    and salts of isomers of ketamine, or an analog thereof;
11        (10.6) 50 grams or more but less than 100 grams of any
12    substance containing hydrocodone, or any of the salts,
13    isomers and salts of isomers of hydrocodone, or an analog
14    thereof;
15        (10.7) (blank); 50 grams or more but less than 100
16    grams of any substance containing dihydrocodeinone, or any
17    of the salts, isomers and salts of isomers of
18    dihydrocodeinone, or an analog thereof;
19        (10.8) 50 grams or more but less than 100 grams of any
20    substance containing dihydrocodeine, or any of the salts,
21    isomers and salts of isomers of dihydrocodeine, or an
22    analog thereof;
23        (10.9) 50 grams or more but less than 100 grams of any
24    substance containing oxycodone, or any of the salts,
25    isomers and salts of isomers of oxycodone, or an analog
26    thereof;

 

 

10000HB2534ham001- 51 -LRB100 08419 RLC 23080 a

1        (11) 50 grams or more but less than 200 grams of any
2    substance containing a substance classified in Schedules I
3    or II, or an analog thereof, which is not otherwise
4    included in this subsection.
5    (c-5) (Blank).
6    (d) Any person who violates this Section with regard to any
7other amount of a controlled or counterfeit substance
8containing dihydrocodeinone or dihydrocodeine or classified in
9Schedules I or II, or an analog thereof, which is (i) a
10narcotic drug, (ii) lysergic acid diethylamide (LSD) or an
11analog thereof, (iii) any substance containing amphetamine or
12fentanyl or any salt or optical isomer of amphetamine or
13fentanyl, or an analog thereof, or (iv) any substance
14containing N-Benzylpiperazine (BZP) or any salt or optical
15isomer of N-Benzylpiperazine (BZP), or an analog thereof, is
16guilty of a Class 2 felony. The fine for violation of this
17subsection (d) shall not be more than $200,000.
18    (d-5) (Blank).
19    (e) Any person who violates this Section with regard to any
20other amount of a controlled substance other than
21methamphetamine or counterfeit substance classified in
22Schedule I or II, or an analog thereof, which substance is not
23included under subsection (d) of this Section, is guilty of a
24Class 3 felony. The fine for violation of this subsection (e)
25shall not be more than $150,000.
26    (f) Any person who violates this Section with regard to any

 

 

10000HB2534ham001- 52 -LRB100 08419 RLC 23080 a

1other amount of a controlled or counterfeit substance
2classified in Schedule III is guilty of a Class 3 felony. The
3fine for violation of this subsection (f) shall not be more
4than $125,000.
5    (g) Any person who violates this Section with regard to any
6other amount of a controlled or counterfeit substance
7classified in Schedule IV is guilty of a Class 3 felony. The
8fine for violation of this subsection (g) shall not be more
9than $100,000.
10    (h) Any person who violates this Section with regard to any
11other amount of a controlled or counterfeit substance
12classified in Schedule V is guilty of a Class 3 felony. The
13fine for violation of this subsection (h) shall not be more
14than $75,000.
15    (i) This Section does not apply to the manufacture,
16possession or distribution of a substance in conformance with
17the provisions of an approved new drug application or an
18exemption for investigational use within the meaning of Section
19505 of the Federal Food, Drug and Cosmetic Act.
20    (j) (Blank).
21(Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17.)
 
22    (720 ILCS 570/402)  (from Ch. 56 1/2, par. 1402)
23    Sec. 402. Except as otherwise authorized by this Act, it is
24unlawful for any person knowingly to possess a controlled or
25counterfeit substance or controlled substance analog. A

 

 

10000HB2534ham001- 53 -LRB100 08419 RLC 23080 a

1violation of this Act with respect to each of the controlled
2substances listed herein constitutes a single and separate
3violation of this Act. For purposes of this Section,
4"controlled substance analog" or "analog" means a substance,
5other than a controlled substance, which is not approved by the
6United States Food and Drug Administration or, if approved, is
7not dispensed or possessed in accordance with State or federal
8law, and that has a chemical structure substantially similar to
9that of a controlled substance in Schedule I or II, or that was
10specifically designed to produce an effect substantially
11similar to that of a controlled substance in Schedule I or II.
12Examples of chemical classes in which controlled substance
13analogs are found include, but are not limited to, the
14following: phenethylamines, N-substituted piperidines,
15morphinans, ecgonines, quinazolinones, substituted indoles,
16and arylcycloalkylamines. For purposes of this Act, a
17controlled substance analog shall be treated in the same manner
18as the controlled substance to which it is substantially
19similar.
20    (a) Any person who violates this Section with respect to
21the following controlled or counterfeit substances and
22amounts, notwithstanding any of the provisions of subsections
23(c) and (d) to the contrary, is guilty of a Class 1 felony and
24shall, if sentenced to a term of imprisonment, be sentenced as
25provided in this subsection (a) and fined as provided in
26subsection (b):

 

 

10000HB2534ham001- 54 -LRB100 08419 RLC 23080 a

1        (1) (A) not less than 4 years and not more than 15
2        years with respect to 15 grams or more but less than
3        100 grams of a substance containing heroin;
4            (B) not less than 6 years and not more than 30
5        years with respect to 100 grams or more but less than
6        400 grams of a substance containing heroin;
7            (C) not less than 8 years and not more than 40
8        years with respect to 400 grams or more but less than
9        900 grams of any substance containing heroin;
10            (D) not less than 10 years and not more than 50
11        years with respect to 900 grams or more of any
12        substance containing heroin;
13        (2) (A) not less than 4 years and not more than 15
14        years with respect to 15 grams or more but less than
15        100 grams of any substance containing cocaine;
16            (B) not less than 6 years and not more than 30
17        years with respect to 100 grams or more but less than
18        400 grams of any substance containing cocaine;
19            (C) not less than 8 years and not more than 40
20        years with respect to 400 grams or more but less than
21        900 grams of any substance containing cocaine;
22            (D) not less than 10 years and not more than 50
23        years with respect to 900 grams or more of any
24        substance containing cocaine;
25        (3) (A) not less than 4 years and not more than 15
26        years with respect to 15 grams or more but less than

 

 

10000HB2534ham001- 55 -LRB100 08419 RLC 23080 a

1        100 grams of any substance containing morphine;
2            (B) not less than 6 years and not more than 30
3        years with respect to 100 grams or more but less than
4        400 grams of any substance containing morphine;
5            (C) not less than 6 years and not more than 40
6        years with respect to 400 grams or more but less than
7        900 grams of any substance containing morphine;
8            (D) not less than 10 years and not more than 50
9        years with respect to 900 grams or more of any
10        substance containing morphine;
11        (4) 200 grams or more of any substance containing
12    peyote;
13        (5) 200 grams or more of any substance containing a
14    derivative of barbituric acid or any of the salts of a
15    derivative of barbituric acid;
16        (6) 200 grams or more of any substance containing
17    amphetamine or any salt of an optical isomer of
18    amphetamine;
19        (6.5) (blank);
20        (7) (A) not less than 4 years and not more than 15
21        years with respect to: (i) 15 grams or more but less
22        than 100 grams of any substance containing lysergic
23        acid diethylamide (LSD), or an analog thereof, or (ii)
24        15 or more objects or 15 or more segregated parts of an
25        object or objects but less than 200 objects or 200
26        segregated parts of an object or objects containing in

 

 

10000HB2534ham001- 56 -LRB100 08419 RLC 23080 a

1        them or having upon them any amount of any substance
2        containing lysergic acid diethylamide (LSD), or an
3        analog thereof;
4            (B) not less than 6 years and not more than 30
5        years with respect to: (i) 100 grams or more but less
6        than 400 grams of any substance containing lysergic
7        acid diethylamide (LSD), or an analog thereof, or (ii)
8        200 or more objects or 200 or more segregated parts of
9        an object or objects but less than 600 objects or less
10        than 600 segregated parts of an object or objects
11        containing in them or having upon them any amount of
12        any substance containing lysergic acid diethylamide
13        (LSD), or an analog thereof;
14            (C) not less than 8 years and not more than 40
15        years with respect to: (i) 400 grams or more but less
16        than 900 grams of any substance containing lysergic
17        acid diethylamide (LSD), or an analog thereof, or (ii)
18        600 or more objects or 600 or more segregated parts of
19        an object or objects but less than 1500 objects or 1500
20        segregated parts of an object or objects containing in
21        them or having upon them any amount of any substance
22        containing lysergic acid diethylamide (LSD), or an
23        analog thereof;
24            (D) not less than 10 years and not more than 50
25        years with respect to: (i) 900 grams or more of any
26        substance containing lysergic acid diethylamide (LSD),

 

 

10000HB2534ham001- 57 -LRB100 08419 RLC 23080 a

1        or an analog thereof, or (ii) 1500 or more objects or
2        1500 or more segregated parts of an object or objects
3        containing in them or having upon them any amount of a
4        substance containing lysergic acid diethylamide (LSD),
5        or an analog thereof;
6        (7.5) (A) not less than 4 years and not more than 15
7        years with respect to: (i) 15 grams or more but less
8        than 100 grams of any substance listed in paragraph
9        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10        (20.1), (21), (25), or (26) of subsection (d) of
11        Section 204, or an analog or derivative thereof, or
12        (ii) 15 or more pills, tablets, caplets, capsules, or
13        objects but less than 200 pills, tablets, caplets,
14        capsules, or objects containing in them or having upon
15        them any amount of any substance listed in paragraph
16        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
17        (20.1), (21), (25), or (26) of subsection (d) of
18        Section 204, or an analog or derivative thereof;
19            (B) not less than 6 years and not more than 30
20        years with respect to: (i) 100 grams or more but less
21        than 400 grams of any substance listed in paragraph
22        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
23        (20.1), (21), (25), or (26) of subsection (d) of
24        Section 204, or an analog or derivative thereof, or
25        (ii) 200 or more pills, tablets, caplets, capsules, or
26        objects but less than 600 pills, tablets, caplets,

 

 

10000HB2534ham001- 58 -LRB100 08419 RLC 23080 a

1        capsules, or objects containing in them or having upon
2        them any amount of any substance listed in paragraph
3        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
4        (20.1), (21), (25), or (26) of subsection (d) of
5        Section 204, or an analog or derivative thereof;
6            (C) not less than 8 years and not more than 40
7        years with respect to: (i) 400 grams or more but less
8        than 900 grams of any substance listed in paragraph
9        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
10        (20.1), (21), (25), or (26) of subsection (d) of
11        Section 204, or an analog or derivative thereof, or
12        (ii) 600 or more pills, tablets, caplets, capsules, or
13        objects but less than 1,500 pills, tablets, caplets,
14        capsules, or objects containing in them or having upon
15        them any amount of any substance listed in paragraph
16        (1), (2), (2.1), (2.2), (3), (14.1), (19), (20),
17        (20.1), (21), (25), or (26) of subsection (d) of
18        Section 204, or an analog or derivative thereof;
19            (D) not less than 10 years and not more than 50
20        years with respect to: (i) 900 grams or more of any
21        substance listed in paragraph (1), (2), (2.1), (2.2),
22        (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of
23        subsection (d) of Section 204, or an analog or
24        derivative thereof, or (ii) 1,500 or more pills,
25        tablets, caplets, capsules, or objects containing in
26        them or having upon them any amount of a substance

 

 

10000HB2534ham001- 59 -LRB100 08419 RLC 23080 a

1        listed in paragraph (1), (2), (2.1), (2.2), (3),
2        (14.1), (19), (20), (20.1), (21), (25), or (26) of
3        subsection (d) of Section 204, or an analog or
4        derivative thereof;
5        (8) 30 grams or more of any substance containing
6    pentazocine or any of the salts, isomers and salts of
7    isomers of pentazocine, or an analog thereof;
8        (9) 30 grams or more of any substance containing
9    methaqualone or any of the salts, isomers and salts of
10    isomers of methaqualone;
11        (10) 30 grams or more of any substance containing
12    phencyclidine or any of the salts, isomers and salts of
13    isomers of phencyclidine (PCP);
14        (10.5) 30 grams or more of any substance containing
15    ketamine or any of the salts, isomers and salts of isomers
16    of ketamine;
17        (11) 200 grams or more of any substance containing any
18    substance classified as a narcotic drug in Schedules I or
19    II, or an analog thereof, which is not otherwise included
20    in this subsection.
21    (b) Any person sentenced with respect to violations of
22paragraph (1), (2), (3), (7), or (7.5) of subsection (a)
23involving 100 grams or more of the controlled substance named
24therein, may in addition to the penalties provided therein, be
25fined an amount not to exceed $200,000 or the full street value
26of the controlled or counterfeit substances, whichever is

 

 

10000HB2534ham001- 60 -LRB100 08419 RLC 23080 a

1greater. The term "street value" shall have the meaning
2ascribed in Section 110-5 of the Code of Criminal Procedure of
31963. Any person sentenced with respect to any other provision
4of subsection (a), may in addition to the penalties provided
5therein, be fined an amount not to exceed $200,000.
6    (c) Any person who violates this Section with regard to an
7amount of a controlled substance other than methamphetamine or
8counterfeit substance not set forth in subsection (a) or (d) is
9guilty of a Class 4 felony. The fine for a violation punishable
10under this subsection (c) shall not be more than $25,000.
11    (d) Any person who violates this Section with regard to any
12amount of anabolic steroid is guilty of a Class C misdemeanor
13for the first offense and a Class B misdemeanor for a
14subsequent offense committed within 2 years of a prior
15conviction.
16(Source: P.A. 99-371, eff. 1-1-16.)".